

Press Note

Syngene through Biocon Foundation partners with NIMHANS for BHUMI

Bangalore, 10, December 2021

Syngene International partners with the National Institute of Mental Health and Neurosciences (NIMHANS) through the Biocon Foundation to help address the growing mental health concerns among the urban population as a part of the Bangalore Urban Mental Health Initiative (BUMHI). As an extension of this commitment, the organisations today announced the launch of the Self Care Health Kits intended to improve the community's knowledge base in protecting and promoting mental health. Designed on the Self Care and Informal Care approaches, the Self Care Health Kits provide individuals with the skills and knowledge required to help build mental health resilience, prevent mental illness, and promote mental health. As the next phase of the initiative, the organisations will also empower community members through adequate training on psychological first aid for common mental ailments, helping improve the overall health and wellness in the community.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA. For more details, visit www.syngeneintl.com

Contact details

Investor Contact	Media Contact
Krishnan G P: +91 80 6891 9807 M: +919819992927 Fax: +91 80 2852 3423 E: krishnan.g@syngeneintl.com	Shotorupa Ghosh M: +91 8450977080 Fax: +91 80 2852 3423 E: Shotorupa.ghosh@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates.

There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.